ArticleACS omega2026
Feasibility of Polylactic Acid-Polycaprolactone-Blended Microspheres in Transarterial Embolization Therapy.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transarterial embolization (TAE) is a minimally invasive endovascular therapy used for tumor devascularization, hemorrhage control, and the treatment of vascular malformations. In particulate TAE, embolic microspheres are delivered through microcatheters to occlude target vessels, and the clinical outcome strongly depends on the particle uniformity, deliverability, mechanical compliance, and intravascular biocompatibility. However, currently available biodegradable embolic materials often degrade too rapidly, leading to premature recanalization, and their acidic degradation products may induce local inflammatory responses. Therefore, degradable microspheres with tunable mechanical properties and a controllable degradation behavior are needed. In this study, polylactic acid/polycaprolactone (PLA/PCL) blend microspheres were fabricated using an emulsion solvent evaporation method with varying PLA/PCL ratios and systematically evaluated. Incorporation of PCL modulated microsphere surface morphology and improved particle deformability, while compression testing demonstrated a progressive reduction in apparent Young's modulus compared with neat PLA. Hemolysis and cytotoxicity assays confirmed that the P-(LA/CL)-73 formulation exhibited nonhemolytic behavior and good cytocompatibility. In addition, P-(LA/CL)-73 demonstrated enhanced thrombus formation, controlled and sustained degradation, and improved distal embolization performance in a 3D-printed in vitro vascular model. These findings suggest that P-(LA/CL) blend microspheres, particularly P-(LA/CL)-73, represent a promising biodegradable embolic platform with tunable mechanical and degradation properties for next-generation TAE applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.